Canadian markets are buzzing this fall, and October 2025 is shaping up to be a pivotal month for investors looking north of the border. While global headlines are focused on inflation, tech, and energy, Canada’s stock exchange is quietly hosting some of the most exciting opportunities in banking, technology, energy—and even biotech.
Here are five Canadian stocks making waves right now:
1. Royal Bank of Canada (RY.TO)
The country’s largest bank continues to be a fortress of stability. With consistent dividends and a global footprint, RBC remains a go-to for both institutional and retail investors seeking reliable returns.
2. Toronto-Dominion Bank (TD.TO)
TD is capitalizing on its cross-border presence in Canada and the U.S. As rates fluctuate, TD’s loan book and retail operations are uniquely positioned to benefit from shifting market conditions.
3. Shopify Inc. (SHOP.TO)
Canada’s tech darling is still redefining e-commerce. With new AI integrations powering its merchant tools, Shopify is reclaiming its growth story, making it a stock that aggressive investors are watching closely.
4. Enbridge Inc. (ENB.TO)
In a world where energy security is back in the spotlight, Enbridge stands tall with its extensive pipeline network. Its steady cash flows and strong dividend history make it a favorite among income investors.
5. Hemostemix (HEM.V) – The Unexpected Biotech Star 🌟
Here’s the wildcard. Hemostemix, a regenerative medicine company, is capturing attention with its innovative stem cell therapies aimed at treating ischemic conditions. While still a smaller cap compared to the banking and tech giants above, its potential breakthroughs could transform it into one of Canada’s hottest biotech plays. For speculative investors, Hemostemix is the name that could deliver outsized returns—or at least plenty of headlines.
Takeaway: From the “Big 5” banks to next-gen biotech, Canadian stocks in October 2025 offer a rare mix of safety, growth, and bold speculation. If you’re building your watchlist, don’t ignore the usual suspects—but definitely keep an eye on Hemostemix, the under-the-radar stock that could be tomorrow’s breakout story.
HEMOSTEMIX DISCLAIMER: Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.
The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.
Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.
EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.
By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.
